ATAXION
Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases. Located in Cambridge, Massachusetts, Ataxion was founded in April 2013 out of the Atlas Venture seed program by Dr. Josh Resnick and Atlas Venture Development Corporation Managing Director and Ataxion Board Member David Grayzel, MD.
ATAXION
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2013-04-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.ataxiontherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
(617)588-2644
Total Funding:
17 M USD
Similar Organizations
ARCH Venture Partners
ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Glycostem Therapeutics
Glycostem is a clinical stage biotech company developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells.
Pathway Bioventures
Pathway Bioventures is a seed-stage life sciences fund investing in next-generation therapeutics, medical device, and diagnostics companies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Biogen Idec
Biogen Idec investment in Series A - Ataxion
Atlas Venture
Atlas Venture investment in Series A - Ataxion
Official Site Inspections
http://www.ataxiontherapeutics.com
Unable to get host informations!!!
